Anika Therapeutics Reports 2Q19 Orthobiologic Revenue of $26.5MM, +1% vs. 2Q18


Anika Therapeutics continued strong ex-U.S. viscosupplement performance while preparing to broaden its portfolio and U.S. market access.

International viscosupplement sales were up nearly 28% year over year.
Due to marketing efforts by Anika’s sales partner, Mitek, MONOVISC volume grew by 18% and ORTHOVISC volume by 9%...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us